Table 1.

Patients characteristics

Patient # (age)		PSA (ng/mL) at FTT-PET	Tumor histology (GS)	Therapy prior to imaging	Therapy following Imaging	PARP1 IHC scores	Genomic aberrations and biopsy site
“WT” mutations	1 (56)	355.10	*de novo mHSPC (5 + 4 = 9)	Treatment naïve	ADT and docetaxel	8	RB1 LOF (left acetabulum)
	2 (79)	30.47	de novo mHSPC (4 + 5 = 9)	Treatment naïve	ADT and docetaxel	8	TP53 LOF (liver)
	4 (63)	12.89	mCRPC 4 + 3 = 7	No therapy (on break from ADT)	ADT and apalutamide	N/A	Heterozygous RAD50 pathogenic mutation (peripheral blood^)
	6 (71)	73.10	mCRPC (4 + 4 = 8)	ADT	Olaparib and ADT	8	CDK12 LOF (parasternal soft tissue mass),ATM (0.2% by ctDNA¥, peripheral blood)
“MUT” mutations	3 (76)	88.86	mCRPC (4 + 5 = 9)	ADT	Olaparib and ADT	7	Somatic BRCA2 copy number loss (iliac bone)
	5 (80)	7.85	mCRPC (5 + 4 = 9)	ADT	Docetaxel and ADT	N/A	ATM LOF (lymph node)
	7 (66)	17.46	mCRPC (4 + 3 = 7)	Olaparib	Cabazitaxel	N/A	Heterozygous germline BRCA2 pathogenic variant (peripheral blood#)
	8 (67)	44.72	mHSPC (4 + 3 = 7)	pTVG-HP and pembrolizumab	Olaparib and ADT	N/A	Germline BRCA2 pathogenic variant and somatic BRCA2 copy number loss (LOH) (sacrum)
	9 (62)	130.10	mHSPC (4 + 4 = 8)	Docetaxel and ADT	Olaparib and ADT	N/A	Germline BRCA2 pathogenic variant (adrenal)

MUT BRCA1/2 and ATM pathogenic variants, WT all other mutations, GS Gleason score, mHSPC metastatic hormone sensitive prostate cancer, * de novo mHSPC with neuroendocrine features, mCRPC metastatic castration-resistant prostate cancer, ADT androgen deprivation therapy, LOF loss of function, LOH loss of heterozygosity, ctDNA circulating tumor DNA prostate cancer. ^Germline analysis via Ambry Genetics assay. #Germline analysis via Myriad Genetics. ¥ctDNA analysis via Guardant 360; pTVG-HP = pTVG-HP is a plasmid DNA, produced in E. coli, that encodes the complementary deoxyribonucleic acid (cDNA) for human prostatic acid phosphatase (PAP). Administered as part of a clinical trial with pembrolizumab